North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma
Robert R. McWilliams; Nathan R. Foster; Michelle R. Mahoney; Thomas C. Smyrk; Joseph A. Murray; Matthew M. Ames; L. Elise Horvath; Daniel J. Schneider; Timothy J. Hobday; Aminah Jatoi; Jeffrey P. Meyers; Matthew P. Goetz
Author Information: Division of Medical Oncology
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.